These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 17391293

  • 1. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
    Pathak A, Hanon O, Negre-Pages L, Sevenier F, OSCAR investigators.
    Fundam Clin Pharmacol; 2007 Apr; 21(2):199-205. PubMed ID: 17391293
    [Abstract] [Full Text] [Related]

  • 2. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [Abstract] [Full Text] [Related]

  • 3. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
    Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nádházi Z, Petrella R, Sedefdjian A, Sévenier F, Shlyakhto EV, Pathak A.
    J Hypertens; 2008 Aug; 26(8):1642-50. PubMed ID: 18622244
    [Abstract] [Full Text] [Related]

  • 4. Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
    Ram CV, Rudmann MA.
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1003-11. PubMed ID: 18035916
    [Abstract] [Full Text] [Related]

  • 5. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A, Muñoz A, Arcos E, López JS, Relats J, ETAPA-2 study investigators.
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [Abstract] [Full Text] [Related]

  • 6. Association between eprosartan-based hypertension therapy and improvement in cognitive function score: long-term follow-up from the OSCAR observational study.
    Hanon O, Lee YS, Pathak A, OSCAR Publication Group.
    J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):366-73. PubMed ID: 23748626
    [Abstract] [Full Text] [Related]

  • 7. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 8. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study.
    Petrella RJ, Shlyakhto E, Konradi AO, Berrou JP, Sedefdjian A, Pathak A, OSCAR Publication GroupFrom the Department of Family Medicine and Cardiology, Lawson Health Research Institute, University of Western Ontario, Ontario, Canada ; 1 the VA Almazov Federal Center for Heart, Blood and Endocrinology, St Petersburg, Russia ; 2 Global Medical Affairs, Abbott Products Operations, Allschwil, Switzerland ; 3 Evidence Based Communication, Chemin de la Jonchère, Rueil-Malmaison, France ; 4 and the Department of Clinical Pharmacology, Centre Hospitelier Universitaire de Toulouse, INSERM-URM-1048, U de Toulouse III Paul Sabatier, Toulouse, France 5..
    J Clin Hypertens (Greenwich); 2012 Feb; 14(2):78-84. PubMed ID: 22277139
    [Abstract] [Full Text] [Related]

  • 9. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study.
    Radaideh GA, Choueiry P, Ismail A, Eid E, Berrou JP, Sedefdjian A, Sévenier F, Pathak A.
    Vasc Health Risk Manag; 2011 Feb; 7():491-5. PubMed ID: 21915165
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV.
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [Abstract] [Full Text] [Related]

  • 11. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
    Conter HS, McKay DW, Reiz RJ.
    Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
    [Abstract] [Full Text] [Related]

  • 12. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
    Labiós M, Martínez M, Gabriel F, Guiral V, Munoz A, Aznar J.
    Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
    [Abstract] [Full Text] [Related]

  • 13. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
    Hanon O, Latour F, Seux ML, Lenoir H, Forette F, Rigaud AS, REAL.FR Group.
    J Nutr Health Aging; 2005 Sep; 9(2):106-11. PubMed ID: 15791354
    [Abstract] [Full Text] [Related]

  • 14. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
    Ametov AS, Demidova TIu, Kosykh SA.
    Klin Med (Mosk); 2006 Sep; 84(2):50-5. PubMed ID: 16613007
    [Abstract] [Full Text] [Related]

  • 15. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE.
    Drugs Exp Clin Res; 2004 Sep; 30(3):125-32. PubMed ID: 15366789
    [Abstract] [Full Text] [Related]

  • 16. [Isolated systolic hypertension and cognitive function in the aged. Experience of the Syst-Eur study].
    Seux ML, Thijs L, Forette F.
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1169-72. PubMed ID: 9404430
    [Abstract] [Full Text] [Related]

  • 17. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S, Hammersen F, Kulschewski A, Frerichs A, Frieg R, Hahnheiser D, Reich G, Schnieders M, Schrandt G, Schrader J.
    Dtsch Med Wochenschr; 2006 Nov 17; 131(46):2580-5. PubMed ID: 17096303
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of eprosartan in diabetic hypertensive patients.
    Robles NR, Martín-Agueda B, López-Muñoz F, Alamo C, Investigators of ESTEPP Study.
    Eur J Intern Med; 2008 Jan 17; 19(1):27-31. PubMed ID: 18206598
    [Abstract] [Full Text] [Related]

  • 19. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A, Ram CV.
    Curr Med Res Opin; 2007 Nov 17; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [Abstract] [Full Text] [Related]

  • 20. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study.
    Akram J, Sheikh UE, Mahmood M, Donnelly R.
    Curr Med Res Opin; 2007 Dec 17; 23(12):2929-36. PubMed ID: 17931463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.